
    
      We are examining the efficacy and safety of oxytocin or oxytocin and tibolone with an
      antidepressant (SSRIs) in treatment resistant depression in a double-blind randomized
      clinical trial.

      A secondary objective is the evaluation of neurobiological factors contributing to drug
      efficacy in treatment resistant depression.
    
  